SCHEMBL4754019

SCHEMBL4754019

CC1(C)Cc2cc(Br)cc(O)c2O1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.37
ALOX12 P18054 1/20 0.37
HTR2A P28223 1/20 0.35
ALDH1A1 P00352 4/20 0.35
LMNA P02545 3/20 0.33
KDM4E B2RXH2 2/20 0.33
NPC1 O15118 1/20 0.33
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33
HTT P42858 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MAPT P10636 2/20 0.32
DHFR P00374 1/20 0.32
AKT1 P31749 1/20 0.31
CYP3A4 P08684 1/20 0.31
TSHR P16473 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
PKM P14618 2/20 0.31
NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30079686 1.00 ALOX15 (0.37) ALOX15ALOX12HTR2AALDH1A1LMNA
SCHEMBL23667871 0.80 SELL (0.37) HTR2AALDH1A1LMNAKDM4EGAA
SCHEMBL1895782 0.79 ALDH1A1 (0.36) HTR2AALDH1A1LMNAMAPTDHFR
SCHEMBL21634429 0.79 HTR2A (0.38) HTR2ALMNADHFR
SCHEMBL23667872 0.79 HTR2A (0.38) HTR2AALDH1A1LMNAKDM4EMAPT
SCHEMBL4750485 0.79 HTR2A (0.51) HTR2AALDH1A1LMNAAKT1PKM
SCHEMBL2437696 0.78 FFAR4 (0.38) HTR2ALMNADHFRFFAR4
SCHEMBL2434136 0.77 LMNA (0.39) ALDH1A1LMNAKDM4EMAPTPKM
SCHEMBL11114171 0.76 ALOX15 (0.35) ALOX15ALOX12ALDH1A1AKT1
SCHEMBL2328393 0.76 KMT2A (0.39) HTR2AALDH1A1LMNAKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110964023-B Fused tetracyclic compounds and application thereof in medicines 广东东阳光药业有限公司 2022-12-27 CN disclosed
US-11447498-B2 Fused tetracyclic compounds and uses thereof in medicine SUNSHINE LAKE PHARMA CO., LTD. (CN) 2022-09-20 US disclosed
US-20220041614-A1 FUSED TETRACYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2022-02-10 US disclosed
US-20220041614-A1 FUSED TETRACYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2022-02-10 US disclosed
CN-110964023-A Fused tetracyclic compounds and application thereof in medicines 广东东阳光药业有限公司 2020-04-07 CN disclosed
WO-2020063870-A1 FUSED TETRACYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2020-04-02 WO disclosed
WO-2008146064-A1 NEW BENZOFURAN DERIVATIVES AS SELECTIVE 5HT7 RECEPTOR INHIBITORS AND PROCESS FOR THEIR PREPARATION EGIS GYÓGYSZERGYÁR (HU) 2008-12-04 WO disclosed
US-20040186170-A1 Benzofuran derivatives, pharmaceutical composition containing the same, and a process for the preparation of the active ingredient EGIS GYOGYSZERGYAR (HU) 2004-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11447498-B2 Fused tetracyclic compounds and uses thereof in medicine SLC10A1, CYP4A11, CYP11B2 ALOX15 423/4885ALOX12 425/4885HTR2A 4190/4885
US-20040186170-A1 Benzofuran derivatives, pharmaceutical composition containing the same, and a process for the preparation of the active ingredient CYP2F1, CYP3A4, CYP2S1 ALOX15 496/4885ALOX12 604/4885HTR2A 826/4885
US-20220041614-A1 FUSED TETRACYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE SLC10A1, CYP4A11, CYP11B2 ALOX15 423/4885ALOX12 425/4885HTR2A 4190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.